You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration

    SBC: CRIMSON BIOPHARM INC            Topic: NCI

    PROJECT SUMMARY The epidermal growth factor receptor (EGFR) gene is mutated and/or amplified in majority of primary glioblastoma (GBM). While EGFR-mutant GBM cancer cells are dependent on EGFR signaling for survival, numerous small molecule EGFR tyrosine kinase inhibitors (TKIs) have failed to show efficacy in this disease. There are two main reasons for these failures: i) Many of these EGFR-TKIs ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Feasibility and design of a novel smartphone app to deliver blood pressure-lowering inspiratory muscle strength training

    SBC: KLEIN BUENDEL, INC.            Topic: NHLBI

    PROJECT SUMMARYHigh blood pressure (BP), particularly high systolic BP (SBP), is the major modifiable risk factor for cardiovascular diseases (CVD) and related conditions. Indeed, over 50% of all adults have above-normal SBP (≥120 mmHg), placing them at increased disease risk. In addition, these adults face ~$2000/year in excess medical expenses compared to their peers with normal BP. Rates of B ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Targeted ColQ gene therapy for Congenital Myasthenic Syndromes

    SBC: Amplo Biotechnology, Inc.            Topic: 106

    PROJECT SUMMARY Congenital Myasthenic Syndromes (CMS) are a group of clinically similar neuromuscular transmission disorders that differ in their underlying genetic mutation. While some phenotypical variation exists, CMS are commonly characterized by muscle weakness (myasthenia) that worsens with physical exertion. Defects in Collagen Q (ColQ), a multidomain functional protein of the Neuro Muscula ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis

    SBC: Briopryme Biologics, Inc.            Topic: 102

    PROJECT SUMMARY Radiation therapy is a widely used treatment modality for pelvic malignancies such as prostate and cervical cancer; however, the high doses needed to confer therapeutic benefit often inflict significant damage on the normal issue in and surrounding the radiation field. The most frequent complication of pelvic radiation is proctitis, which nearly all patients experience acutely and ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Audiom: Developing an Indoor Non-Visual Mapping System

    SBC: XR NAVIGATION INC            Topic: NEI

    Project Abstract Indoor navigation for blind and visually impaired individuals (BVIs) within unfamiliar locations is typically an incredibly anxiety-provoking and stressful experience for numerous reasons, e.g., inaccessible signage including directories and venue maps, and if braille signs do exist, they are difficult to find, lack directional information, and are useless to the BVIs who do not r ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing of a computer-based multimodal mind and body approach for mild cognitive decline

    SBC: BRAIN THRIVE TECHNOLOGY LLC            Topic: NIA

    Summary Mild cognitive impairment (MCI) represents an intermediate state between normal aging and the diagnosis of clinically probable very early Alzheimer's disease (AD). Since MCI manifests before the onset of AD, it may be the optimal stage in which to intervene with preventative therapies for AD and age-related dementia before progressive neurological loss and irreversible cognitive impairment ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Fluorescence lifetime imaging device for 5-ALA-guided neurosurgery

    SBC: HILIGHT SURGICAL, INC.            Topic: 394

    PROJECT SUMMARY 5-ALA-induced PpIX fluorescence-guided surgery (FGS) enables real-time visualization of residual cancer tissue during resection of brain tumors. This addresses a critical need in surgical oncology as the ability to identify residual tumor leads to improvements in overall survival, whereas the sparing of normal tissue benefits the patient’s quality of life. Currently, surgeons vis ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Low Cost W-Band Imaging Array

    SBC: MILLIMETER WAVE SYSTEMS LLC            Topic: CBD22BT001

    Low-cost systems operating at video rates within W-band have remained elusive – especially for stand-off and remote applications. Real time video rate imaging requires parallel detection modalities that traditionally led to high costs and calibration challenges. Substantial advances in low-cost packaging and chip-level integration driven by commercial millimeter-wave applications can now be appl ...

    STTR Phase I 2023 Department of DefenseOffice for Chemical and Biological Defense
  9. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY Lupus is a chronic, systemic autoimmune disease in which cells of the immune system attack organ systems throughout the body including the kidneys, brain, and lungs and that presents heterogeneously with symptoms that can include fever, arthritis, alopecia, stroke, and heart attack. Lupus is driven by autoreactive B and CD4 T cells with a particular role for TfH and TH17 CD4 T cell ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A digital tool for monitoring speech decline in ALS

    SBC: MODALITY.AI , INC            Topic: NIDCD

    PROJECT SUMMARY Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagno ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government